American Regent to acquire France API manufacturing facility of Daiichi Sankyo.

American Regent, a US manufacturer of pharmaceuticals for human and veterinary use with manufacturing, agreed to acquire France active pharmaceutical ingredient manufacturing facility of Daiichi Sankyo, a global pharmaceutical company. Financial terms were not disclosed. "We now have the ability to directly collaborate with colleagues in France. This vital connection will allow us to more quickly mobilize production resources in getting Adequan to veterinarians and, ultimately, patients. Additionally, this acquisition provides the opportunity to explore other products for manufacture, so American Regent can continue to find innovative ways of responding to customer needs," Joel Steckler, American Regent's Vice President of Animal Health.